Bladder cancer gets new treatment

Bladder cancer gets new treatment, new FDA-approved drug


The FDA has just approved a new bladder cancer drug known as Tecentriq (atezolizumab), which is intended to treat the most common type of bladder cancer. This is the first drug in its class to be approved to treat bladder cancer. Dr. Richard Pazdur, director of the office of hematology and oncology products in the FDA’s Center for Drug Evaluation and Research, said in a news release, “Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway. Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body’s immune system and its interaction with cancer cells.”

The drug was approved for use in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.
The approval comes following a clinical trial, which was completed on 310 patients with locally advanced or metastatic urothelial carcinoma. Nearly 15 percent of patients saw shrinkage in their tumor lasting for at least two months and up to 14 months.

Tumor response occurred in 26 percent of patients who were positive for PD-L1 expression, compared with 9.5 percent of those who were negative for PD-L1 expression.

Common side effects of Tecentriq were fatigue, decreased appetite, nausea, urinary tract infection, fever, and constipation. Some side effects may affect healthy organs like the lungs or heart, concluded the FDA.

Also, read Bel Marra Health’s article on 3 signs you may have a bladder problem.


Author Bio

Mohan Garikiparithi got his degree in medicine from Osmania University (University of Health Sciences). He practiced clinical medicine for over a decade before he shifted his focus to the field of health communications. During his active practice he served as the head of the Dept. of Microbiology in a diagnostic centre in India. On a three-year communications program in Germany, Mohan developed a keen interest in German Medicine (Homoeopathy), and other alternative systems of medicine. He now advocates treating different medical conditions without the use of traditional drugs. An ardent squash player, Mohan believes in the importance of fitness and wellness.

Advertisement

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm

Popular Stories